Widespread resistance mutations to sulfadoxine-pyrimethamine in malaria parasites imported to China from Central and Western Africa

Luyi Zhao,1, Liang Pi,1, Yucheng Qin,1, Yuxin Lu,2, Weilin Zeng,3, Zheng Xiang,4, Pien Qin,5, Xi Chen,6, Cuiying Li,7, Yanmei Zhang,8, Siqi Wang,8, Yu Si,9, Gongchao Yang,10, Benjamin M. Rosenthal,11, Yaming Huang,5,6,7,8, Zhaqing Yang,10, Jun Li,12

† Department of Pathogen Biology and Immunology, Kunming Medical University, Kunming, 650500, Yunnan, PR China
2 Shanglin County People’s Hospital, Shanglin, 530500, Guangxi, PR China
3 Department of Neurobiology and Anatomical Sciences, University of Mississippi Medical Center, 2500, North State Street, USA
4 Animal Parasitic Disease Laboratory, Agricultural Research Service, US Department of Agriculture, 10300 Baltimore Avenue, Beltsville, MD, 20705, USA
5 Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control, Nanning, 530021, Guangxi, PR China
6 Department of Pathogen Biology and Immunology, Kunming Medical University, Kunming, 650500, Yunnan, PR China
7 Department of Neurobiology and Anatomical Sciences, University of Mississippi Medical Center, 2500, North State Street, USA
8 Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control, Nanning, 530021, Guangxi, PR China
9 Department of Pathogen Biology and Immunology, Kunming Medical University, Kunming, 650500, Yunnan, PR China
10 Shanglin County People’s Hospital, Shanglin, 530500, Guangxi, PR China
11 Department of Neurobiology and Anatomical Sciences, University of Mississippi Medical Center, 2500, North State Street, USA
12 Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control, Nanning, 530021, Guangxi, PR China

ABSTRACT

Keywords: Africa Anti-malarial drug resistance Sulfadoxine–pyrimethamine Plasmodium falciparum

1. Introduction

Malaria is the most important vector-borne disease and remains a preeminent global public health problem. In 2016, 91 countries reported approximately 216 million cases of malaria and a global death toll of about 445,000 (World Health Organization, 2017a) African countries, especially in sub-Saharan Africa, account for 90% of malaria cases and deaths (World Health Organization, 2017a) The majority of human malaria is caused by five species, namely, Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale and Plasmodium knowlesi (Miller et al., 2002). In Africa, P. falciparum is the predominant species of malaria (World Health Organization, 2017a).

Malaria used to be one of the most important infectious disease in China (Li Jun and Zhang, 1360). Since the Chinese Government
initiated the National Malaria Elimination Program in 2010, malaria transmission has obviously been reduced. There has been no indigenous cases reported in China since 2017 (Zhang et al., 2018). However, migrant workers and travelers between China and other countries have increased in recent years. Hence, imported malaria cases have markedly increased in the Guangxi Zhuang Autonomous Region. And the most of imported cases were *P. falciparum* from Africa (Zhang et al., 2018). An outbreak of imported malaria took place in 2013 in Shanglin, Guangxi Zhuang Autonomous Region (Wei Shujiao et al., 2013).

Sulfadoxine-pyrimethamine (SP) is no longer used for treatment of clinical malaria in Africa because of widespread resistance (Curts et al., 1998; Sibley et al., 2001). However, it continues to be used as an intermittent preventive treatment during pregnancy (IPTp) in malaria-endemic areas in Africa. In sub-Saharan Africa, IPTp-SP has been shown to reduce maternal anemia, low birth weight and perinatal mortality (World Health Organization, 2018). Seasonal malaria chemoprevention (SMC) with amodiaquine (AQ) plus SP (AQ + SP) for children aged 3–59 months reduces the incidence of clinical attacks and severe malaria by about 75% (World Health Organization, 2018). SP is also provided as intermittent preventive treatment in infants (IPTi) in areas of moderate-to-high malaria transmission of Africa, however, no countries have reported implementation of an IPTi policy as of 2015, Sierra Leone began implementing IPTi on a pilot basis in one district in 2016 (World Health Organization, 2017a, 2017b, 2018). WHO is calling on all malaria-affected countries in sub-Saharan Africa and their development partners to adopt and implement IPTi-SP (World Health Organization, 2017b). Yet the decline in the efficacy of SP had already emerged in Africa, and levels of SP resistance vary within Africa (Naidoo and Roper, 2013), boding ill for the future.

To inform current policy on continuing use of SP, surveillance of SP resistance levels must be achieved by monitoring of molecular markers and by describing its geographical distribution. SP resistance is linked with dihydrofolate reductase (dhfr) in the folate biosynthetic pathway, and substitutions of amino acids in the enzymes dihydroprotoerato synthetase (*dhps*) (Aubouy et al., 2003). Resistance to SP is caused by point mutations in the *dhfr* and *dhps* genes of *P. falciparum* (Roper et al., 2003). In the *dhfr* gene, the mutations N51I, C59R, S108N and I164L are associated with pyrimethamine resistance (Cowman et al., 1988; Peterson et al., 1988). In the *dhps* gene, mutations have been identified in codons 436, 437, 540, 581 and 613 that confer resistance to dihydroprotroate (Brooks et al., 1994; Triglia et al., 1997). The combination of a triple *dhfr* (N51I/C59R/S108N) mutant with a double *dhps* (A437G/K540E) mutant is a useful predictor of clinical SP treatment failure and results in limited efficacy of SP-IPTi (Kublin et al., 2002). The triple mutant *pfdfhr* with the *pfdfps* single mutant 437G also has been found to be associated with treatment failure in Western and Central Africa (Kun et al., 1999; Dunojo et al., 2006; Picot et al., 2009).

In addition, the WHO recommended that SP-IPTi should not be implemented when the prevalence of *dhps* K540E exceeds 50% (Intermittent Preventive). A recent meta-analysis demonstrated that IPTP efficacy was reduced when the prevalence of A581G exceeds 10% in Africa (Chico et al., 2015). This situation may suggest discontinuation of IPTP. In some parts of East Africa, other findings reported that SP-IPTi and IPTP have failed in the quintuple mutant (N51I/C59R/S108N + A437G/K540E) acquired *pfdfhs* A581G (Picot et al., 2009; Gesase et al., 2009). According to reports, an unusual 1431V mutation in *dhps* gene has been seen to emerge in combination with A436S, A437G, A581G and A613S in Africa (Sutherland et al., 2009; Oguine et al., 2016). Although there was no available data show that higher SP resistance is associated with an increasing number of these mutations, these mutations do favor resistance risk.

In Western Africa and Central Africa, the combination of *dhfr* N51I, N59R, and S108N with *dhps* A437G has been demonstrated to be prevalent (Naidoo and Roper, 2013). However, we know little about drug resistance imported from Western Africa to China in recent years (Yang et al., 2019; Xu et al., 2018). Therefore, we evaluated polymorphisms and the geographic distribution of haplotypes of *pfdfhr* and *pfdfhs* imported in China from Western Africa, which would help provide information on imported *P. falciparum* malaria cases in China and future treatment policy with IPTp for the two clinical populations.

2. Methods

2.1. Samples collection and DNA extraction

Blood samples were obtained from malaria cases who returned from Africa to Guangxi Province, China between 2016 and 2018. Malaria infections were diagnosed by microscopic examination of Giemsa-stained thick and thin blood films. The questionnaires of all cases were recorded, including gender, ethnicity, occupation, microscopic examination results and travel history. The human subject protocol for this study was by the Shanglin Hospital Institutional Review Board. All participants supplied written informed consent. Prospective cases with complex travel histories were excluded from the study.

Parasite DNA was extracted from whole blood using the High Pure PCR Template Preparation Kit (Roche) according to the manufacturer's instructions. Then *P. falciparum* infection was confirmed using a nested polymerase chain reaction (PCR) targeting the small subunit ribosomal RNA gene as described previously (Snounou, 2002; Snounou and Singh, 2002). The DNA template was kept at −20 °C until use.

2.2. Amplification and sequencing of *pfdfhr* and *pfdfhs* gene

Only infections containing strains *P. falciparum* by genotyping were used for sequencing analysis. Those associated with resistance to SP were investigated by examining four codons of *pfdfhr* (N51I, C59R, S108N and I164L) and six codons of *pfdfhs* (I431V, S436 A/F, A437G, K540 E/N, A581G and A613T) (Cowman et al., 1988; Peterson et al., 1988; Brooks et al., 1994; Triglia et al., 1997). The *pfdfhr* and *pfdfhs* gene were amplified using primers and conditions as described earlier (Garg et al., 2009). Briefly, primary PCR was performed in a total volume of 20 μL containing 2 μL DNA template, 10 μL Premix Taq Version 2.0 (TakaRa, USA), 1 μL of each primer, and 6 μL ddH2O. The secondary PCR was performed in a total volume of 40 μL containing 2 μL primary PCR product, 20 μL Premix Taq Version 2.0 (TakaRa, USA), 1 μL of each primer, and 19 μL ddH2O. Positive PCR products were sequenced by Generalbiol (Chuzhou, China). The forward and reverse sequences were aligned using DNAstar (version 7.1) software and were manually refined to obtain a better consensus nucleotide sequence. The consensus sequences of *pfdfhr* and *pfdfhs* gene were multiple-aligned with a reference sequence of the gene retrieved from the GeneBank database using BioEdit (version 7.2.5). The GeneBank accession numbers of the *pfdfhr* and *pfdfhs* reference sequences were PF3D7_0417200.1 and PF3D7_0810800.1, respectively. The nucleotide sequences of the multiple alignments for each gene were translated into their corresponding amino acid sequences and manually analyzed for mutations at the specified codons.

2.3. Statistical analysis

Statistical analysis was carried out with the SPSS software (version 22). The chi-square test was used to compare the categorical variables among the groups. A p-value of < 0.05 was considered statistically significant.

3. Results

3.1. Characteristics of study participants

A total of 243 *P. falciparum* cases returning to Guangxi Province from 8 countries of Africa between March 2016 and September 2018 were enrolled in this study. These patients returned from four countries.
in Western Africa (78.6%, 191/243): Liberia, Sierra Leone, Mali, Ghana, and four countries located in Central Africa (21.4%, 52/243): Congo, Cameroon, the Democratic Republic of the Congo (DRC), Central African Republic (Fig. 1). Most of those from Ghana came from Kumasi or Asankragua. There were 235 male patients and 8 female patients. The distribution of patients by age ranged from 15 to 64, the mean age was 38.9 ± 9.9 years. All patients received targeted antimalarial treatment according to the guidelines of antimalarial drugs in China.

3.2. P. falciparum pfdhfr gene analysis

A total of 208 cases were successfully sequenced for codons 51, 59, 108, 164 of pfdhfr gene, 165 in Western African and 43 in Central Africa. A high prevalence of Pfdhfr mutant isolates was observed in this study. The pfdhfr mutations at codons 51, 59 and 108 were prevalent in each geographic region (> 85%) (Table 1). In addition, C59R and S108N were near saturation in our study. The I164L mutant was present, but rare, with no evident regional difference between Western and Central Africa (P > 0.05).

The genotypes of pfdhfr are presented in Table 2. About 165 isolates returned from 4 countries in Western Africa followed 5 haplotypes. Only 11 of 165 isolates (6.67%) were wild type N51C59S108I164, meaning nearly 95% harbored at least one mutation. The most prevalent of these (71.5%) was the triple-mutant haplotype triple-mutant haplotype IRNI, followed by a quadruple-mutant IRNL (11.5%), and two double mutants ICNI (3.0%) and NRNI (7.3%). As in Western Africa, wild-type haplotypes were only infrequently encountered in the 43 isolates derived from Central Africa (7%), Here too, the triple-mutant IRNI was also by far the most prevalent (86.1%). Other haplotypes included the quadruple-mutant IRNL (4.7%) and the double-mutant NRNI (2.3%). In addition, the double-mutant NRNI was only detected in five patients who returned from Ghana, Western Africa. Significant differences among groups were not observed with these mutations (P > 0.05). No mixed haplotypes were identified.

3.3. Analysis of pfdhps gene

The pfdhps gene was successfully sequenced in 147 Western African and 40 Central African isolates. The prevalence distribution of pfdhps mutation is summarized in Table 1. None of which were entirely wild-type.

The I431V and A581G mutant allele were observed only from Ghana in Western Africa. The most frequent pfdhps mutation (A437G) was prevalent everywhere, but significantly more so in Western Africa (87.8%) than in Central Africa (70.0%) (χ² = 5.966, P < 0.05).

Fifteen different genotypes were found in patients returned from Western Africa (Table 2). Prevalence of the wild-type haplotype did not significantly vary regionally. In Western Africa, the double-mutant IA/GKAA was most common in patients who returned from Ghana. It was significantly higher in Western than Central Africa (χ² = 4.968, P < 0.05). There were 7 different genotypes of pfdhps gene found in patients returned from Central Africa. The common genotype was IS/GKAA. In addition, single-mutant haplotypes IA/FKAA was significantly higher in Central Africa than Western Africa (χ² = 4.410, P < 0.05).

3.4. Pfdhfr and pfdhps haplotypes analysis

As summarized in Table 3, multiple mutations that contribute to SP resistance in both pfdhfr and pfdhps genes were detected in this study, comprising more than twenty pfdhfr/pfdhps haplotypes, none of which

| Gene   | Codon   | % (n) of isolates | Western Africa | Central Africa | P     |
|--------|---------|-------------------|----------------|----------------|-------|
| pfdhfr | N51I    | 86.1 (142)        | 90.7 (39)      | 0.611           |
|        | C59R    | 90.3 (149)        | 93.0 (40)      | 0.799           |
|        | S108N   | 93.3 (154)        | 93.0 (40)      | 1               |
|        | I164L   | 11.5 (19)         | 4.7 (2)        | 0.295           |
| pfdhps | I431V   | 0.7 (1)           | 0.0 (0)        | 1.000           |
|        | S436 A/F| 57.1 (84)         | 45.0 (18)      | 0.211           |
|        | A437G   | 87.8 (129)        | 70.0 (28)      | 0.015*          |
|        | K540 E/N| 12.9 (19)         | 10.0 (4)       | 0.820           |
|        | A581G   | 11.6 (17)         | 0.0 (0)        | 0.052           |
|        | A613 S/T| 10.9 (16)         | 5.0 (2)        | 0.414           |

*: P < 0.05.
than Central Africa (I42.1%) in Cameroon, Central Africa. However, the quintuple mutant (I) was especially prevalent in patients returned from Ghana, Western Africa. The evolution and widespread dissemination of malarial resistance to sulfadoxine-pyrimethamine has restricted its clinical use in Africa to intermittent preventive treatment during pregnancy (IPTp), in infants (IPTi) and SMC (World Health Organization, 2018). Among 39 African countries on IPTp in 2017, about 22% of pregnant women received three or more doses of IPTp, compared with 17% in 2015 and 0% in 2010 (World Health Organization, 2018). Current guidelines in

were entirely wild-type. The quadruple mutant IAAYAA/IRNI was significantly higher in Central Africa (\(\chi^2 = 8.623, P < 0.05\)). The quadruple mutant (IAAYAA/IRNI) was presented in high proportion (42.1%) in Cameroon, Central Africa. However, the quintuple mutant (IAAYAA/IRNI) haplotypes were significantly higher in Western Africa than Central Africa (\(\chi^2 = 7.801, P < 0.05\)). Results showed that a prevalence of 46.2% (42/91) \(pfdfhr/pfdhps\) quintuple (IAAYAA/IRNI) was especially prevalent in patients returned from Ghana, Western Africa. However, the quadruple mutant (IAAYAA/IRNI) was presented in high proportion (42.1%) in Cameroon, Central Africa.

### Table 2

Prevalence of \(pfdfhr\) and \(pfdhps\) haplotypes in isolates.

| Gene     | Haplotype | Total | Western Africa | Central Africa | P* |
|----------|-----------|-------|----------------|----------------|----|
|          |           |       | Liberia | Sierra Leone | Mali | Ghana | Congo | Cameroon | Congo, DRC | Central Africa Republic |
|          |           |       | % (n) | % (n) | % (n) | % (n) | % (n) | % (n) | % (n) | % (n) |
| pfdfhr   | N = 165   | N = 7 | N = 3 | N = 1 | N = 154 | N = 43 | N = 10 | N = 24 | N = 5 | N = 4 |
|          |           |       |       |       |       |       |       |       |       |       |
|          | NCSI (WT) | 6.7 (11) | 0 | 0 | 100.00 (1) | 6.5 (10) | 7.0 (3) | 10.00 (1) | 8.3 (2) | 0 | 0 | 0.792 |
|          | ICNI      | 3.0 (5) | 0 | 0 | 0 | 3.3 (5) | 0 | 0 | 32.0 (8) | 0 | 0 | 0.551 |
|          | NINR      | 7.3 (12) | 14.3 (1) | 100 (3) | 0 | 5.2 (8) | 2.3 (1) | 10.00 (1) | 0 | 0 | 0.401 |
|          | IRNI      | 71.5 (118) | 85.7 (6) | 0 | 72.7 (112) | 86.1 (37) | 70.00 (7) | 91.7 (22) | 80.0 (4) | 100.0 (4) | 0.051 |
|          | IRNL      | 11.5 (19) | 0 | 0 | 12.3 (19) | 4.7 (2) | 10.00 (1) | 0 | 20.0 (1) | 0 | 0.296 |

\(a\): \(P < 0.05\).  
\* Comparison between Western Africa and Central Africa.

### Table 3

Prevalence of \(pfdfhr/pfdhps\) genotype.

| Gene     | No. of mutations | Total | Western Africa | Central Africa | P* |
|----------|------------------|-------|----------------|----------------|----|
|          |                  |       | Liberia | Sierra Leone | Ghana | Congo | Congo, DRC | Cameroon |
|          | pfdfhr/pfdhps    |       | % (n) | % (n) | % (n) | % (n) | % (n) | % (n) |
|          | genotype         |       |       |       |       |       |       |       |       |
|          | N = 98           | N = 5 | N = 2 | N = 91 | N = 21 | N = 1 | N = 1 | N = 19 |
|          | IAYAA/AAYAA      | 1 | 0 | 0 | 0 | 4.8 (1) | 0 | 0 | 5.3 (1) | 0.394 |
|          | IAYAA/AAYAA      | 2 | 0 | 0 | 0 | 4.8 (1) | 0 | 0 | 5.3 (1) | 0.394 |
|          | IAYAA/AAYAA      | 3 | 4.1 (4) | 20.0 (1) | 0 | 3.3 (3) | 4.8 (1) | 0 | 5.3 (1) | 1 |
|          | IAYAA/AAYAA      | 3 | 1.0 (1) | 20.0 (1) | 0 | 0 | 9.5 (2) | 0 | 10.5 (2) | 0.137 |
|          | IAYAA/AAYAA      | 3 | 2.0 (2) | 0 | 0 | 2.2 (2) | 0 | 0 | 1 |
|          | IAYAA/AAYAA      | 4 | 2.0 (2) | 0 | 0 | 2.2 (2) | 0 | 0 | 1 |
|          | IAYAA/AAYAA      | 4 | 1.0 (1) | 0 | 0 | 1.1 (1) | 0 | 0 | 0 |
|          | IAYAA/AAYAA      | 4 | 4.1 (4) | 0 | 0 | 4.4 (4) | 0 | 0 | 0 |
|          | IAYAA/AAYAA      | 4 | 10.2 (10) | 0 | 50.00 (1) | 9.9 (9) | 38.1 (8) | 0 | 42.1 (8) | 0.003* |
|          | IAYAA/AAYAA      | 5 | 2.0 (2) | 0 | 0 | 2.2 (2) | 4.8 (1) | 0 | 5.3 (1) | 0.445 |
|          | IAYAA/AAYAA      | 5 | 45.9 (45) | 60.0 (3) | 0 | 46.2 (42) | 14.3 (3) | 0 | 50.0 (1) | 10.5 (2) | 0.001* |
|          | IAYAA/AAYAA      | 5 | 3.1 (3) | 0 | 50.00 (1) | 2.2 (2) | 14.3 (3) | 0 | 15.7 (3) | 0.113 |
|          | IAYAA/AAYAA      | 5 | 9.2 (9) | 0 | 0 | 9.9 (9) | 0 | 0 | 0.322 |
|          | IAYAA/AAYAA      | 6 | 2.0 (2) | 0 | 0 | 2.2 (2) | 0 | 0 | 1 |
|          | IAYAA/AAYAA      | 6 | 1.0 (1) | 0 | 0 | 1.10 (1) | 0 | 0 | 1 |
|          | IAYAA/AAYAA      | 6 | 1.0 (1) | 0 | 0 | 1.10 (1) | 0 | 0 | 0 |
|          | IAYAA/AAYAA      | 7 | 9.2 (9) | 0 | 0 | 9.9 (9) | 0 | 0 | 1 |
|          | IAYAA/AAYAA      | 7 | 1.0 (1) | 0 | 0 | 1.10 (1) | 0 | 0 | 1 |
|          | IAYAA/AAYAA      | 7 | 1.0 (1) | 0 | 0 | 1.10 (1) | 0 | 0 | 1 |

\(a\): \(P < 0.05\).  
* Comparison between Western Africa and Central Africa.

### 4. Discussion

The evolution and widespread dissemination of malarial resistance to sulfadoxine-pyrimethamine has restricted its clinical use in Africa to intermittent preventive treatment during pregnancy (IPTp), in infants (IPTi) and SMC (Curris et al., 1998; Sibley et al., 2001). In 2016, 15 million children in 12 countries in Africa’s Sahel subregion were protected through SMC (World Health Organization, 2018). Among 39 African countries on IPTp in 2017, about 22% of pregnant women received three or more doses of IPTp, compared with 17% in 2015 and 0% in 2010 (World Health Organization, 2018). Current guidelines in
China call for the use of ACT treatment (Ministry of Health, 2009). For uncomplicated *P. falciparum* patients, ACTs routinely include oral compound tablets of dihydroartemisinin plus piperaquine (DHA + PQ), artesunate plus amodiaquine (AS + AQ), and ART + PQ (Ministry of Health, 2016). All patients in this study were treated with intravenous (IV) injections of artesunate for 3 days (on day 0 with 120 mg, and 60 mg on subsequent 2 days) in the hospital. Upon resolution of their symptoms, patients were discharged and two days of oral treatment with dihydroartemisinin-piperaquine (DHP) was prescribed.

Our purpose was to better understand the spectrum of malarial parasites being imported to China from Africa, where such resistance is widespread, in order to shed light on clinical options and limitations for such patients, and to assess risks associated with the spread of resistant malarial parasites. Such molecular epidemiology is needed in order to elucidate dynamic epidemiological features and to provide policy makers with information needed to develop better safeguards for such travelers and for the populations to which they return. Unfortunately, we cannot determine from these data, whether in the same locality, certain resistance haplotypes are co-circulating, which would further accelerate the development of resistance phenotypes comprised of combinations of mutations not previously known to co-occur in the same parasite genome.

Historically, malaria was highly prevalent in the Guangxi Zhuang Autonomous Region of China. Subsequent national anti-malarial campaigns proved highly successful in this region, stemming indigenous transmission. Recently, however, the region has experienced a dramatic rise in imported cases, owing to an increase in migrant workers who have lived in regions that remain endemic for malaria. In China, before travelling to Africa, all patients received health education conducted by local CDCs, including training about malaria transmission and personal protection. Tablets of chloroquine or piperaquine were recommended as prophylaxis.

Here, we investigated mutations of *pfdhfr* and *pfdhps* in the parasites of migrant workers returning to Shanglin, Guangxi Zhuang Autonomous Region from Africa (World Health Organization, 2017b) between 2016 and 2018. As The WHO recommends that SP-IPTi has been implemented only when the prevalence of the K540E mutation is not excess 50% (Intermittent Preventive). In this study, mutant K540 E/N did not exceed 50% among migrants returned from Central and Western Africa. This may favor continued efficacy of SP-IPTi in this region, but its protection in these workers (12.9%) is much higher than 0.00%–3.00% prevalence reported in Ghana 2005–2010, when sulfadoxine/pyrimethamine SP first replaced chloroquine as the drug for IPTp in 2005 (Duah et al., 2012; Koram et al., 2005). A recent analysis concluded that IPTp efficacy was reduced when the prevalence of AS81G exceeds 10% (Chico et al., 2015). Ours is the first to suggest prevalence above that threshold in Ghana (11.6%), calling for increased surveillance to monitor the efficacy of sulfadoxine/pyrimethamine there.

Among the migrant workers studied here, the single-mutant type ISGKAA was the predominant haplotype in Cameroon, consistent with published data in this region during 2014–2015 (Nkoli Mandoko et al., 2018). This single-mutant was the most prevalent haplotype in Ghana in 2005 (Pearce et al., 2009), however, in our study, double-mutant type IAGKAA became the predominant haplotype (37.0%) in patients returned from Ghana, indicating growing drug resistance there, driven by an increase in A436G.

In our study, the mutation IAAGKAA/IRNI is significantly higher in Central Africa, and the mutation IAGKAA/IRNI is significantly higher in Western Africa. The quadruple ISGKAA/IRNI was not obviously different from previous reports in Ghana (Duah et al., 2012). For the first time, a high prevalence (46.2%) of quintuple *pfdhfr/pfdhps* resistance (ISGKAA/IRNI) is evident in Ghana. Available data do not definitively associate the above mutations with strong drug resistance, so the clinical implications of such new haplotypes require further study. The difference haplotype of *pfdhfr* and *pfdhps* that we have observed among imported samples may be related to differences in treatment schemes among the countries in Africa. According to reports, the ISGEOA/IRNI mutation is a significant predictor of clinical treatment failure and results in limited protective value of SP-IPTi (Kublin et al., 2002; Gosling et al., 2009). In our study, this quintuple mutant was observed in Ghana (2.2%) and Cameroon (15.7%) with rare prevalence. It may suggest that SP for IPTI and IPTP is still efficient among these countries. ISGEOA/IRNI, adds *pfdhps* 581G and *dhfr* 1164L were linked very high levels of SP failure, called ‘super resistance’ (Gesase et al., 2009). For the first time, we found 1.1%, 9.9% respectively for IRNI/ISGEOA and IRNL/ISGEOA.

5. Conclusions

Taken together, our study reinforces that resistance of *P. falciparum* to SP continues to increase in Central and Western Africa, and that study of imported cases can provide valuable information on the genetic basis for such clinically-relevant phenotypic evolution in source and recipient countries. The high prevalence of resistance may now, or in the near future, abrogate the efficacy of even intermittent treatment of pregnant women or infants with sulfadoxine-pyrimethamine. This is a matter of great clinical consequence and bears on public health policy.
concerning treatment policy for imported malaria in China. Fortunately, ACTs treatment remains effective in China.

Acknowledgments

The authors thank all the patients for volunteering to participate in the study. This study was supported by the National Science Foundation of China (31860604 and U1802286). Major science and technology projects of Yunnan Province (2018F00081). CL, XC and YZ were supported by Yunnan Applied Basic Research Projects-Union Foundation (2017FE468-185, 2018FE001-190, 2015FB034 respectively. YQ was supported by Guangxi Zhuang Autonomous Region Health Commission of Scientific Research Project (Z20190892). YL was funded by grants of the Science and Technology Bureau Programs for Science and Technology Development of Nanning, Guangxi Zhuang Autonomous Region, China (ZC20153012).

References

Alifrangis, M., Lusingu, J.P., Biggs, R.A., et al., 1998. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. U.S.A. 95 (23), 13949–13953. https://doi.org/10.1073/pnas.95.23.13949. published Online First: Epub Date.

Ministry of Health, 2009. Beijing, China.Antimalarial Drug Policy in China. World Health Organization, 2018. World Malaria Report. World Health Organization, 2017b. Malaria Prevention Works Let’s Close the Map. World Health Organization, 2013. Malaria among asymptomatic pregnant women in Southeast Nigeria. Parasitol. Res. 117 (3), 1621–1633. https://doi.org/10.1007/s00436-018-5754-5. published Online First: Epub Date.

Sibbey, C.H., Hyde, J.E., Sims, P.F., et al., 2001. Pyrimethamine-sulfadoxine resistance in a population of Plasmodium falciparum in Africa. J. Infect. Dis. 189 (8), 1174–1181. https://doi.org/10.1086/329591. published Online First: Epub Date.

Shang, H., Zhang, X., Li, Y., et al., 2018. Antimicrobial resistance in Plasmodium falciparum in Mozambican infants. J. Infect. Dis. 218 (7), 1066–1074. https://doi.org/10.1093/infdis/jiy010. published Online First: Epub Date.

Royal Society, World Health Organization, 2007. An Update of the World Malaria Report 2007. World Health Organization, 2017. Malaria Report. World Health Organization, 2017b. Malaria Prevention Works Let’s Close the Map. World Health Organization, 2018. World Malaria Report.

Peterson, D.S., Walliker, D., Laryea, K.K., et al., 2002. Molecular markers for Pfmdr1 and Pfkelch13 polymorphisms in African Plasmodium falciparum imported to Canada. Mol. Biochem. Parasitol. 2013. 2012.0202. published Online First: Epub Date.

Dunyo, S., Ord, H., Hallett, R., et al., 2006. Randomised trial of chloroquine/sulfadoxine-pyrimethamine in Gambian children with malaria: impact against multidrug-resistant P. falciparum. PLoS Clin. Trials, 1 (1), e1.4. published Online First: Epub Date.

IJP: Drugs and Drug Resistance 12 (2020) 1–6

Zhao, et al.

IJP: Drugs and Drug Resistance 12 (2020) 1–6

Zhao, et al.

IJP: Drugs and Drug Resistance 12 (2020) 1–6

Zhao, et al.

IJP: Drugs and Drug Resistance 12 (2020) 1–6

Zhao, et al.

IJP: Drugs and Drug Resistance 12 (2020) 1–6

Zhao, et al.